-
Lynn E. Taylor, MD, Miriam Hospital, Providence,
RI. Personal communication; 2005.
-
Sherman KE, Rouster SD, Chung RT,
Rajicic N. Hepatitis C virus prevalence among patients infected with
human immunodeficiency virus: a cross-sectional analysis of the US
adult AIDS Clinical Trials Group. Clin Infect
Dis. 2002;34:831-7.
-
Sulkowski
MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann
Intern Med. 2003;138(3):197-207.
-
Thomas DL. Hepatitis C and human immunodeficiency
virus infection. Hepatology. 2002;36(5 suppl 1):S201-9.
-
Graham CS,
Koziel MJ. First things first: balancing hepatitis C and human immunodeficiency
virus. Clin Infect Dis. 2003;36(3):368-9.
-
Armstrong GL, Simard EP,
Wasley A, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis
C virus (HCV) in the United States, 1999-2002. Paper presented at:
55th Annual Meeting of the American Association for the Study of
Liver Diseases; 2004; Boston, MA.
-
Alter MJ. Prevention of spread of
hepatitis C. Hepatology. 2002;36(5 suppl 1):S93-8.
-
Ruys TA, den Hollander
JG, Beld MG, van der Ende ME, van der Meer JT. Sexual transmission
of hepatitis C in homosexual men. [Article in Dutch]. Ned
Tijdschr Geneeskd. 2003;148:2309-12.
-
Fletcher S. Sexual transmission of hepatitis C and
early intervention. J Assoc Nurses AIDS Care. 2003;14(5 suppl):87S-94S.
-
Thomas
DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis
C virus among patients attending sexually transmitted diseases clinics
in Baltimore—an analysis of 309 sex partnerships.
J Infect Dis. 1995;171:768-75.
-
Shev S, Hermodsson S, Lindholm A,
Malm E, Widell A, Norkrans G. Risk factor exposure among hepatitis
C virus RNA positive Swedish blood donors—the
role of parenteral and sexual transmission. Scand
J Infect Dis. 1995;27:99-104.
-
Alberti
A, Chemello L, Benvegnu L. Natural history of hepatitis C. J
Hepatol.
1999;31(suppl 1):17-24.
-
Alter MJ, Margolis HS, Krawczynski K, et
al. The natural history of community-acquired hepatitis C in the
United States. The Sentinel Counties Chronic non-A, non-B Hepatitis
Study Team. N Engl J Med. 1992;327:1899-905.
-
Alter MJ, Kruszon-Moran
D, Nainan OV, et al. The prevalence of hepatitis C virus infection
in the United States, 1988 through 1994. N Engl
J Med. 1999;341:556-62.
-
Gerlach
JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate
of both spontaneous and treatment-induced viral clearance. Gastroenterology.
2003;125:80-8.
-
Kenny-Walsh E. Clinical outcomes after hepatitis
C infection from contaminated anti-D immune globulin. Irish Hepatology
Research Group. N Engl J Med. 1999;340:1228-33.
-
Di Bisceglie AM. Hepatitis
C and hepatocellular carcinoma. Hepatology. 1997;26 (3 suppl 1):34S-38S.
-
Dore
GJ, Freeman AJ, Law M, Kaldor JM. Is severe liver disease a common
outcome for people with chronic hepatitis C? Gastroenterol
Hepatol.
2002;17:423-30.
-
Freeman AJ, Law MG, Kaldor JM, Dore GJ. Predicting
progression to cirrhosis in chronic hepatitis C virus infection.
J Viral Hepat. 2003;10:285-93.
-
Lauer GM, Walker BD. Hepatitis C virus
infection. N Engl J Med. 2001;345:41-52.
-
Poynard T, Bedossa P, Opolon
P. Natural history of liver fibrosis progression in patients with
chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC
groups. Lancet. 1997;349(9055):825-32.
-
Poynard T, Ratziu V, Benmanov
Y, Di Martino V, Bedossa P, Opolon P. Fibrosis in patients with chronic
hepatitis C: detection and significance. Semin
Liver Dis. 2000;20:47-55.
-
Benhamou
Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human
immunodeficiency virus and hepatitis C virus coinfected patients.
The Multivirc Group. Hepatology. 1999;30:1054-8.
-
Martinez-Sierra C,
Arizcorreta A, Diaz F, et al. Progression of chronic hepatitis C
to liver fibrosis and cirrhosis in patients coinfected with hepatitis
C virus and human immunodeficiency virus. Clin
Infect Dis. 2003;36:491-8.
-
Mohsen
AH, Easterbrook PJ, Taylor C, et al. Impact of human immunodeficiency
virus (HIV) infection on the progression of liver fibrosis in hepatitis
C virus infected patients. Gut. 2003;52:1035-40.
-
Soto B, Sanchez-Quijano
A, Rodrigo L, et al. Human immunodeficiency virus infection modifies
the natural history of chronic parenterally-acquired hepatitis C
with an unusually rapid progression to cirrhosis. J
Hepatol. 1997;26:1-5.
-
Di
Bisceglie AM. Hepatitis C. Lancet. 1998;351 (9099):351-5.
-
Marcellin
P. Hepatitis C: the clinical spectrum of the disease. J
Hepatol.
1999;31(suppl 1):9-16.
-
Alter MJ, Margolis HS, Bell BP, et al. Recommendations
for prevention and control of hepatitis C virus (HCV infection and
HCV-related chronic disease. MMWR Morb Mortal
Wkly Rep. 1998;47(RR19):1-39.
-
National
Institutes of Health Consensus Development Conference Statement.
Management of Hepatitis C: 2002. http://consensus.nih.gov/cons/116/091202116cdc_statement.htm.
-
Shruti Mehta, MD, Johns Hopkins University. Personal
communication; 2005.
-
Tedaldi EM, Hullsiek KH, Malvestutto CD, Arduino
RC, Fisher EJ, Gaglio PJ, et al.; Terry Beirn Community Programs
for Clinical Research on AIDS. Prevalence and characteristics of
hepatitis C virus coinfection in a human immunodeficiency virus clinical
trials group: the Terry Beirn Community Programs for Clinical Research
on AIDS. Clin Infect Dis. 2003;36:1313-7.
-
Hare CB, Peters MJ, Watson
JJ, Mark DG, Jacobson MA. Viral hepatitis, liver damage, and antiretroviral
prescribing patterns in an HIV community network. Paper presented
at: Ninth Conference on Retroviruses and Opportunistic Infections;
2002; Seattle, WA. Abstract 662-M.
-
Anderson KB, Guest JL, Rimland
D. Hepatitis C virus coinfection increases mortality in HIV-infected
patients in the highly active antiretroviral therapy era: data from
the HIV Atlanta VA Cohort Study. Clin Infect
Dis. 2004;39:1507-13.
-
Strasfeld
L, Lo Y, Netski D, Thomas DL, Klein RS. The association of hepatitis
C prevalence, activity, and genotype with HIV infection in a cohort
of New York City drug users. J Acquir Immune
Defic Syndr. 2003;33:356-64.
-
Goedert JJ, Eyster ME, Lederman MM, et al. End-stage
liver disease in persons with hemophilia and transfusion-associated
infections. Blood. 2002;100(5):1584-9.
-
Martin-Carbonero L, Benhamou
Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis
in human immunodeficiency virus-infected patients with chronic hepatitis
C: a European collaborative study. Clin Infect
Dis. 2004;38:128-33.
-
Ragni
MV, Belle SH. Impact of human immunodeficiency virus infection on
progression to end-stage liver disease in individuals with hemophilia
and hepatitis C virus infection. J Infect Dis. 2001;183:1112-5.
-
Sulkowski
M, Mehta S, Higgins Y, Torbenson M, Moore R, Thomas D. Unexpected
significant liver disease among HIV/HCV coinfected persons with minimal
fibrosis on initial liver biopsy. Paper presented at: 12th Conference
on Retroviruses and Opportunistic Infections; 2005; Boston, MA. Abstract
121.
-
Ryder SD, Irving WL, Jones DA, Neal KR, Underwood
JC; Trent Hepatitis C Study Group. Progression of hepatic fibrosis
in patients with hepatitis C: a prospective repeat liver biopsy study.
Gut. 2004;53:451-5.
-
Graham CS, Baden LR, Yu E, et al. Influence of
human immunodeficiency virus infection on the course of hepatitis
C virus infection: a meta-analysis. Clin Infect
Dis. 2001;33:562-9.
-
U.S.
Department of Health and Human Services. Guidelines
for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. 2005.
Available at: http://aidsinfo.nih.gov/guidelines/default_db2.asp?id=50.
-
Centers
for Disease Control and Prevention. Treating opportunistic infections
among HIV-infected adults and adolescents. Recommendations from CDC,
the National Institutes of Health, and the HIV Medicine Association/Infectious
Diseases Society of America. MMWR Morb Mortal
Wkly Rep. 2004;53(RR
15):1-112. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/rr5315a1.htm.
-
Strader DB, Wright T, Thomas DL, Seeff LB; American
Association for the Study of Liver Diseases. Diagnosis, management,
and treatment of hepatitis C. Hepatology. 2004;39:1147-71. Available
at: www.aasld.org/eweb/docs/hepatitisc.pdf.
-
Department of Veterans
Affairs. Management and Treatment of Hepatitis
C Virus in HIV-1 Infected Adults: Recommendations from the Veterans
Affairs Hepatitis C Resource Center Program and the National Hepatitis
C Program Office. September
1, 2005. Available at: http://hepatitis.va.gov/vahep?page=tp04-gd-01.
-
Augenbraun
M, Goedert JJ, Thomas D, et al. Incident hepatitis C virus in women
with human immunodeficiency virus infection. Clin
Infect Dis. 2003;37:1357-64.
-
Bhagani
S, Danta M, Hui C, Slapak G, Dusheiko G, Johnson MA. Acute hepatitis
C virus (HCV) in a cohort of HIV positive men: outcomes and response
to pegylated interferon-alfa 2B (PEG-IFN-alfa 2B) and ribavirin.
Paper presented at: 10th Anniversary Conference of the British HIV
Association; 2004; Cardiff, United Kingdom.
-
Danta M, Brown D, Jacobs
M, Dusheiko G, Bhagani S. Epidemiology of acute HCV infection in
a London cohort of HIV positive homosexual males. Paper presented
at: 54th Annual Meeting of the American Association for the Study
of Liver Diseases; 2003; Boston, MA. Abstract 561.
-
Mehta SH, Cox A,
Hoover DR, et al. Protection against persistence of hepatitis C.
Lancet. 2002;359(9316):1478-83.
-
Nelson M, Browne R, Asboe D, Gilleece
Y, Atkins M, Gazzard B. Increasing incidence of acute hepatitis C
in HIV positive men secondary to sexual transmission, epidemiology
and treatment. In: Program and Abstracts of the Ninth European AIDS
Conference; 2003; Warsaw, Poland. Abstract F12/3.
-
Thomas DL, Astemborski
J, Rai RM, et al. The natural history of hepatitis C virus infection:
host, viral, and environmental factors. JAMA. 2000;284:450-6.
-
Alter
HJ. Descartes before the horse: I clone, therefore I am: the hepatitis
C virus in current perspective. Ann Intern Med. 1991;115:644-9.
-
Berggren
R, Jain M, Hester J, Vinson G, Dawson B, Keiser P. False-negative
hepatitis C antibody is associated with low CD4 cell counts in HIV/HCV-coinfected
patients. Paper presented at: Eighth Conference on Retroviruses and
Opportunistic Infections; 2001; Chicago, IL. Abstract 562.
-
Busch MP,
Laycock ME, Mohr B, et al. Failure of serologic assays for diagnosis
of hepatitis B and C virus infections in patients with advanced HIV.
Paper presented at: Eighth Conference on Retroviruses and Opportunistic
Infections; 2001; Chicago, IL. Abstract 235.
-
Fleming CA, Tumilty S,
Murray JE, Nunes D. Challenges in the treatment of patients coinfected
with HIV and hepatitis C virus: need for team care. Clin
Infect Dis.
2005;40(suppl 5):S349-54.
-
Taylor LE. Delivering care to injection
drug users coinfected with HIV and hepatitis C virus. Clin
Infect Dis. 2005;40(suppl 5):S355-61.
-
Michael Harank, RN, Alameda County
Medical Center, Oakland, CA. Personal communication, 2005.
-
Department
of Veteran’s Affairs. Treatment of Patients
with Cirrhosis and Portal Hypertension. Available at: www.hepatitis.va.gov/vahep?page=tp03-03-02-01.
-
Federal
Bureau of Prisons. Clinical Practice Guidelines for the Prevention
and Treatment of Viral Hepatitis. 2003. Available at: http://nicic.org/Library/016972.
-
Koff
RS. Risks associated with hepatitis A and hepatitis B in patients
with hepatitis C. J Clin Gastroenterol. 2001;33:20-6.
-
Vento S, Garofano
T, Renzini C, et al. Fulminant hepatitis associated with hepatitis
A virus superinfection in patients with chronic hepatitis C. N
Engl J Med. 1998;338:286-90.
-
Liaw YF. Hepatitis C virus superinfection
in patients with chronic hepatitis B virus infection. J
Gastroenterol.
2002;37(suppl 13):65-8.
-
Koretz RL, Brezina M, Polito AJ, et al. Non-A,
non-B posttransfusion hepatitis: comparing C and non-C hepatitis.
Hepatology. 1993;17:361-5.
-
Tedaldi EM, Baker RK, Moorman AC, et al.
HIV Outpatient Study (HOPS) Investigators. Hepatitis A and B vaccination
practices for ambulatory patients infected with HIV. Clin
Infect Dis. 2004;38:1478-84.
-
Hess G, Clemens R, Bienzle U, Schonfeld C, Schunck
B, Bock HL. Immunogenicity and safety of an inactivated hepatitis
A vaccine in anti-HIV positive and negative homosexual men. J
Med Virol. 1995;46:40-2.
-
Weissman S, Feucht C, Yarmohammadi H. Response
to Hepatitis A Vaccination in HIV+ Patients. Paper presented at:
11th Conference on Retroviruses and Opportunistic Infections; 2004;
San Francisco, CA. Abstract 830.
-
Litwin AH, Soloway I, Gourevitch
MN. Integrating services for injection drug users infected with hepatitis
C virus with methadone maintenance treatment: challenges and opportunities.
Clin Infect Dis. 2005;40(suppl 5):S339-45.
-
Clanon KA, Johannes Mueller
J, Harank M. Integrating treatment for hepatitis C virus infection
into an HIV clinic. Clin Infect Dis. 2005;40(suppl 5):S362-6.
-
Edlin
BR, Kresina TF, Raymond DB, et al. Overcoming barriers to prevention,
care, and treatment of hepatitis C in illicit drug users. Clin
Infect Dis. 2005;40(suppl 5):S276-85.
-
Margaret Hoffman-Terry, MD, Lehigh
Valley Hospital, Allentown, PA. Personal communication; 2005.
-
Monto
A, Patel K, Bostrom A, et al. Risks of a range of alcohol intake
on hepatitis C-related fibrosis. Hepatology. 2004;39:826-34.
-
Westin
J, Lagging LM, Spak F, et al. Moderate alcohol intake increases fibrosis
progression in untreated patients with hepatitis C virus infection.
J Viral Hepat. 2002;9:235-41.
-
Cooper CL, Cameron WD. Effect of alcohol
use and highly active antiretroviral therapy on plasma levels of
hepatitis C virus (HCV) in patients coinfected with HIV and HCV.
Clin Infect Dis. 2005;41(suppl 1):105-9.
-
Cromie SL, Jenkins PJ, Bowden
DS, Dudley FJ. Chronic hepatitis C: effect of alcohol on hepatitic
activity and viral titre. J Hepatol. 1996;25:821-6.
-
Oshita M, Hayashi
N, Kasahara A, et al. Increased serum hepatitis C virus RNA levels
among alcoholic patients with chronic hepatitis C. Hepatology. 1994;20:1115-20.
-
Kranzler HR, Van Kirk J. Efficacy of naltrexone and
acamprosate for alcoholism treatment: a meta-analysis. Alcohol
Clin Exp Res. 2001;25:1335-41.
-
Kresina TF, Bruce DR, Cargill VA, Cheever
LW. Integrating care for hepatitis C virus (HCV) and primary care
for HIV for injection drug users coinfected with HIV and HCV. Clin
Infect Dis. 2005;41(suppl 1):S83-8.
-
Littleton J, Zieglgansberger W.
Pharmacological mechanisms of naltrexone and acamprosate in the prevention
of relapse in alcohol dependence. Am J Addict. 2003;12(suppl 1):S3-11.
-
Department
of Veterans Affairs. National Hepatitis C Case Registry. Fiscal Year
2003 Report. Available at: www.hepatitis.va.gov/vahep?page=tp03-03-09-03.
-
Sulkowski
MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as
an opportunistic disease in persons infected with human immunodeficiency
virus. Clin Infect Dis. 2000;30 (suppl 1)S77-84.
-
Briat A, Dulioust
E, Galimand J, et al. Hepatitis C virus in the semen of men coinfected
with HIV-1: prevalence and origin. AIDS. 2005;19(16):1827-35.
-
Pasquier
C, Bujan L, Daudin M, et al. Intermittent detection of hepatitis
C virus (HCV) in semen from men with human immunodeficiency virus
type 1 (HIV-1) and HCV. J Med Virol. 2003;69(3):344-9.
-
Nowicki MJ,
Laskus T, Nikolopoulou G, et al. Presence of hepatitis C virus (HCV)
RNA in the genital tracts of HCV/HIV-1-coinfected women. J
InfectDis.
2005; 192(9): 1557-65.
-
Thomas DL, Villano SA, Riester KA, et al. Perinatal
transmission of hepatitis C virus from human immunodeficiency virus
type 1-infected mothers. Women and Infants Transmission Study. J
Infect Dis. 1998;177(6):1480-8.
-
Roberts EA, Yeung L. Maternal-infant
transmission of hepatitis C virus infection. Hepatology. 2002;36(5
suppl 1):S106-13.
-
Pembreya L, Newella ML, Tovob PA; EPHN Collaborators.
The management of HCV infected pregnant women and their children
European paediatric HCV network. J Hepatol. 2005; 43(3):515-25.
-
Carrat
F, Bani-Sadr F, Pol S, et al. ANRS HCO2 RIBAVIC Study Team. Pegylated
interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin,
for chronic hepatitis C in HIV-infected patients: a randomized controlled
trial. JAMA. 2004;292: 2839-48.
-
Chung RT, Andersen J, Volberding P,
et al. AIDS Clinical Trials Group A5071 Study Team. Peginterferon
alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for
chronic hepatitis C in HIV-coinfected persons. N
Engl J Med. 2004;351:451-9.
-
Torriani
FJ, Rodriguez-Torres M, Rockstroh JK, et al. APRICOT Study Group.
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus
infection in HIV-infected patients. N Engl J
Med. 2004;351:438-50.
-
Taylor
LE, Rich JD, Tashima KT. Peginterferon plus ribavirin for hepatitis
C in HIV-infected patients. N Engl J Med. 2004;351:2340-2; author
reply 2340-2.
-
Torriani FJ, Dieterich DT. N
Engl J Med. 2004;351:2340-2;
author reply 2340-2.
-
Chung RT, Anderson J, Volberding P. N
Engl J Med. 2004;351:2340-2; author reply 2340-2.
-
Opravil M, Sasadeusz J,
Cooper D, et al. [Abstract 926]. Effect of baseline CD4 cell count
on efficacy and safety of pegylated interferon a-2a, (Pegasys) plus
ribavirin in HIV/HCV coinfection: The AIDS Pegasys Ribavirin International
Co-infection Trial (APRICOT). Paper presented at: 12th Conference
on Retroviruses and Opportunistic Infections; 2005; Boston, MA.
-
Blatt
LM, Mutchnick MG, Tong MJ, et al. Assessment of hepatitis C virus
RNA and genotype from 6807 patients with chronic hepatitis C in the
United States. J Viral Hepat. 2000;7:196-202.
-
Laguno M, Murillas
J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared
with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected
patients. AIDS. 2004;18:F27-36.
-
Perez-Olmeda M, Nunez M, Romero M,
et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic
hepatitis C in HIV-infected patients. AIDS. 2003;17:1023-8.
-
Cribier
B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F. High hepatitis
C viraemia and impaired antibody response in patients coinfected
with HIV. AIDS. 1995;9:1131-6.
-
Di Martino V, Rufat P, Boyer N, et
al. The influence of human immunodeficiency virus coinfection on
chronic hepatitis C in injection drug users: a long-term retrospective
cohort study. Hepatology. 2001;34:1193-9.
-
Thomas DL, Rich JD, Schuman
P, et al. Multicenter evaluation of hepatitis C RNA levels among
female injection drug users. J Infect Dis. 2001;183:973-6.
-
Centers
for Disease Control and Prevention. HIV/AIDS Surveillance Report.
2003;15:1-46. Available at: www.cdc.gov/hiv/stats/2003surveillancereport.pdf.
-
Daniel
S. Chronic hepatitis C treatment patterns in African American patients:
an update. Am J Gastroenterol. 2005;100:716-22.
-
Jeffers LJ, Cassidy
W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin
for black American patients with chronic HCV genotype 1. Hepatology.
2004;39:1702-8.
-
Muir AJ, Bornstein JD, Killenberg PG; Atlantic Coast
Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for
the treatment of chronic hepatitis C in blacks and non-Hispanic whites.
N Engl J Med. 2004;350:2265-71.
-
Reddy SI ,Ukomadu C. Viral hepatitis
and hepatocellular carcinoma in African Americans. Cancer Epidemiol
Biomarkers Prev. 2003;12:248s-251s.
-
Wiley TE, Brown J, Chan J. Hepatitis
C infection in African Americans: its natural history and histological
progression. Am J Gastroenterol. 2002;97:700-6.
-
Mochida S, Ohnishi
K, Matsuo S, Kakihara K, Fujiwara K. Effect of alcohol intake on
the efficacy of interferon therapy in patients with chronic hepatitis
C as evaluated by multivariate logistic regression analysis. Alcohol
Clin Exp Res. 1996;20(9 suppl):371A-377A.
-
Ohnishi K, Matsuo S, Matsutani
K, et al. Interferon therapy for chronic hepatitis C in habitual
drinkers: comparison with chronic hepatitis C in infrequent drinkers.
Am J Gastroenterol. 1996;91:1374-9.
-
Okazaki T ,Yoshihara H ,Suzuki
K ,et al. Efficacy of interferon therapy in patients with chronic
hepatitis C. Comparison between non-drinkers and drinkers. Scand
J Gastroenterol. 1994;29:1039-43.
-
Tabone M, Sidoli L, Laudi C, et
al. Alcohol abstinence does not offset the strong negative effect
of lifetime alcohol consumption on the outcome of interferon therapy.
J Viral Hepat. 2002;9:288-94.
-
Schaefer M, Schmidt F, Folwaczny C,
et al. Adherence and mental side effects during hepatitis C treatment
with interferon alfa and ribavirin in psychiatric risk groups. Hepatology.
2003;37:443-51.
-
Sylvestre DL. Approaching treatment for hepatitis
C virus infection in substance users. Clin Infect
Dis. 2005;41(suppl
1):S79-82.
-
Churchill DR, Mann D, Coker RJ, et al. Fatal haemorrhage
following liver biopsy in patients with HIV infection. Genitourin
Med. 1996;72:62-4.
-
McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A
21-year experience with major hemorrhage after percutaneous liver
biopsy. Gastroenterology. 1990;99:1396-400.
-
Piccinino F, Sagnelli
E, Pasquale G, Giusti G . Complications following percutaneous liver
biopsy. A multicentre retrospective study on 68,276 biopsies. J
Hepatol.
1986;2:165-73.
-
Bedossa P, Dargere D, Paradis V. Sampling variability
of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449-57.
-
Regev
A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation
in liver biopsy in patients with chronic HCV infection. Am
J Gastroenterol.
2002;97:2614-8.
-
Alberti A, Clumeck N, Collins S, et al; The ECC Jury.
Short Statement of the first European Consensus Conference on the
treatment of chronic hepatitis B and C in HIV co-infected patients.
J Hepatol. 2005;42:615-24.
-
Mauss S, Valenti W, DePamphilis J, et al.
Risk factors for hepatic decompensation in patients with HIV/HCV
coinfection and liver cirrhosis during interferon-based therapy.
AIDS. 2004;18:F21-5.
-
Fung J, Eghtesad B, Patel-Tom K, DeVera M, Chapman
H, Ragni R. Liver transplantation in patients with HIV infection. Liver
Transpl. 2004;10(suppl 2):S39-53.
-
Ragni MV, Belle SH, Im K,
et al. Survival of human immunodeficiency virus-infected liver transplant
recipients. J Infect Dis. 2003;188:1412-20.
-
Roland ME, Adey D, Carlson
LL, Terrault NA. Kidney and liver transplantation in HIV-infected
patients: case presentations and review. AIDS
Patient Care STDS.
2003;17:501-7.
-
Cooper CL. Therapeutic interventions for HIV infection
and chronic viral hepatitis. Clin Infect Dis. 2005;41:S69-72.
-
Fleischer
R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial
toxicity. Clin Infect Dis. 2004;38:e79-80.
-
Brau N, Rodriguez-Torres
M, Prokupek D, et al. Treatment of chronic hepatitis C in HIV/HCV-coinfection
with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin.
Hepatology. 2004;39:989-98.
-
Roche Pharmaceuticals. Pegasys (peg-interferon
alfa-2a). Product information. 2003-2005. Available at: www.rocheusa.com/products/pegasys/.
-
Schering-Plough.
Peg-Intron (peg-interferon alfa-2b). Product information. 2005. Available
at: www.schering-plough.com/schering_ plough/pc/hepatitis.jsp.
-
Fried MW. Side effects of therapy of hepatitis C
and their management. Hepatology. 2002;36(5 suppl 1):S237-44.
-
Chung
RT, Anderson J, Volberding P, et al., AIDS Clinical Trials Group
A5071 Study Team. A randomized, controlled trial of PEG-interferon-alfa-2a
plus ribavirin vs interferon-alfa-2a plus ribavirin for chronic hepatitis
C virus infection in HIV-co-infected persons: follow-up results of
ACTG A5071. Paper presented at: 11th Conference on Retroviruses and
Opportunistic Infections; 2004; San Francisco, CA. Abstract 110.
-
Rodriguez-Torres M, Torriani FJ, Lissen E, et al.
Predictability of sustained virological response (SVR) in patients
with HCV/HIV co-infection during combination therapy with peginterferon
alfa-2A (40KD) (Pegasys) plus ribavirin (Copegus) in the APRICOT
trial. Paper presented at: XV International AIDS Conference; 2004;
Bangkok, Thailand. Abstract MoPeB3304.
-
Lau DT, Kleiner DE, Ghany MG,
Park Y, Schmid P, Hoofnagle JH. 10-year follow-up after interferon-alpha
therapy for chronic hepatitis C. Hepatology. 1998;28:1121-7.
-
Marcellin
P, Boyer N, Gervais A, et al. Long-term histologic improvement and
loss of detectable intrahepatic HCV RNA in patients with chronic
hepatitis C and sustained response to interferon-alpha therapy. Ann
Intern Med. 1997;127:875-81.
-
Sim H, Yim C, Krajden M, Heathcote J.
Durability of serological remission in chronic hepatitis C treated
with interferon-alpha-2B. Am J Gastroenterol. 1998;93:39-43.
-
Imazeki
F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic
hepatitis C after interferon therapy by long-term cohort study. Hepatology.
2003;38:493-502.
-
Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy
prolonged life expectancy among chronic hepatitis C patients. Gastroenterology.
2002;123:483-91.
-
Soriano V, Maida I, Nunez M, et al. Long-term follow-up
of HIV-infected patients with chronic hepatitis C virus infection
treated with interferon-based therapies. Antivir
Ther. 2004;9:987-92.
-
Lissen
E, Clumeck N, Sola R, et al. [Abstract 174]. Histological response
to peginterferon alfa-2A (40KD) (Pegasys) plus ribavirin (Copegus)
in patients with HIV/HCV coinfection: results of the AIDS Pegasys
Ribavirin International Co-infection Trial (APRICOT). Paper presented
at: 55th Annual Meeting of the American Association for the Study
of Liver Diseases; 2004; Boston, MA.
-
Uberti-Foppa C, De Bona A, Morsica
G, et al. Pretreatment of chronic active hepatitis C in patients
coinfected with HIV and hepatitis C virus reduces the hepatotoxicity
associated with subsequent antiretroviral therapy. J
Acquir Immune Defic Syndr. 2003;33:146-52.
-
Jaeckel E, Cornberg M, Wedemeyer H, et
al. German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis
C with interferon alfa-2b. N Engl J Med. 2001;345:1452-7.
-
Gileece
Y, Brown RE, Ashboe D, et al. Transmission of viral hepatitis C among
HIV-positive men and response to a 24 week course of pegylated interferon
and ribavirin. J Acquir Immune Defic Syndr. 2005;40:41-6.
-
Chaix M-L,
Serpaggi J, Batisse D, et al. Homosexually transmitted HCV acute
infection related to a clustered genotype 4 HCV in HIV-1-infected
men and inefficacy of early antiviral therapy. Paper presented at:
12th Conference on Retroviruses and Opportunistic Infections; 2005;
Boston, MA. Abstract 122.
-
Dominguez S, et al. Evaluation of a 24-week
pegylated interferon and ribavirin therapy in HIV patients with acute
HCV. Paper presented at: First International Workshop on HIV and
HCV Co-infection; 2004; Amsterdam, The Netherlands.
-
Nelson M, Browne
R, Asboe D, Gilleece Y, Atkins M, Gazzard B. Increasing incidence
of acute hepatitis C in HIV positive men secondary to sexual transmission,
epidemiology and treatment. Paper presented at: Ninth European AIDS
Conference; 2003; Warsaw, Poland. Abstract F12/3.
-
Vogel M, Bieniek
B, Jessen H, et al. Treatment of acute hepatitis C infection in HIV-infected
patients: a retrospective analysis of eleven cases. J
Viral Hepat.
2005;12:207-11.
-
Alain Litwin, MD, Montefiore Medical Center, Bronx,
NY. Personal communication; 2005.
-
Michael Rigsby, MD, VA National
HIV and Hepatitis C Program, West Haven, CT. Personal communication;
2005.
-
Marian Kerbleski, RN, VA Medical Center, San Francisco,
CA. Personal communication; 2005.
-
Kathleen Clanon, MD, Alameda County
Medical Center, Oakland, CA. Personal communication; 2005.
-
Zucker
SD, Sherman KE. Beyond interferon for hepatitis C: living in the
present while hoping for the future. Gastroenterology. 2004;126:1487-8.
-
Backmund
M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis
C infection in injection drug users. Hepatology. 2001;34:188-93.
-
Van
Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis
C in individuals with a recent history of intravenous drug abuse.
Am J Gastroenterol. 2003;98:2281-8.
-
Dalgard O. Follow-up studies
of treatment for hepatitis C virus infection among injection drug
users. Clin Infect Dis. 2005;40(suppl 5):S336-8.
-
Johnson ME, Brems
C, Burke S. Recognizing comorbidity among drug users in treatment.
Am J Drug Alcohol Abuse. 2002;28(2):243-61.
-
Soto TA, Sadowski LS.
The prevalence of hepatitis C among HIV patients with psychiatric
and substance abuse diagnoses. Paper presented at: XIV International
AIDS Conference; 2002; Barcelona, Spain. Abstract ThPeC7516.
-
Thorberg
FA, Lyvers M. Negative mood regulation (NMR) expectancies, mood,
and affect intensity among clients in substance disorder treatment
facilities. Addict Behav. 2005. In press.
-
Valente SM. Depression and
HIV disease. J Assoc Nurses AIDS Care. 2003;14:41-51.
-
Watkins KE,
Hunter SB, Wenzel SL, et al. Prevalence and characteristics of clients
with co-occurring disorders in outpatient substance abuse treatment.
Am J Drug Alcohol Abuse. 2004;30:749-64.
-
Zdilar D, Franco-Bronson
K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa,
and depression. Hepatology. 2000;31:1207-11.
-
Yun LW, Maravi M, Kobayashi
JS, Barton PL, Davidson AJ. Antidepressant treatment improves adherence
to antiretroviral therapy among depressed HIV-infected patients.
J Acquir Immune Defic Syndr. 2005;38:432-8.
-
Bini EJ, Currie S, Shen
H, et al. Abstract 1064260. Interferon and ribavirin therapy in patients
coinfected with HIV and hepatitis C. Paper presented at Digestive
Disease Week; 2004; New Orleans, Louisiana.
-
Rauch A, Egger M, Reichen
J, Furrer H; Swiss HIV Cohort Study. Chronic hepatitis C in HIV-infected
patients: low eligibility and applicability of therapy with pegylated
interferon-alpha plus ribavirin. J Acquir Immune
Defic Syndr. 2005;38:238-40.
-
Wong
JB, Buti M, Casado MA, Fosbrook L, Soriano V, Esteban R. [Abstract
622]. Cost-effectiveness of peginterferon a-2b plus ribavirin for
chronic hepatitis C in HIV-HCV-co-infected patients. Paper presented
at: 40th Meeting of the European Association for the Study of Liver
Diseases; 2005; Paris, France.
-
Wong JB, McGovern B, Sulkowski MS,
Dieterich DT, Poynard T. [Abstract 225]. Cost-effectiveness implications
of the timing of peginterferon alfa-2b plus ribavirin for chronic
hepatitis C in HIV-HCV co-infected patients. Paper presented at:
Digestive Disease Week; 2004; New Orleans, LA.
-
National Association
of State and Territorial AIDS Directors. Upublished data; 2005.
-
Linda
Anders, Maryland ADAP Program, Baltimore, MD. Personal communication;
2005.
-
Cheever L. HIV and HCV: HAB’s Role. Slide 14:
ADAP HCV treatment claims (9/01). Slide presentation. Rockville,
MD: HIV/AIDS Bureau, Health Resources and Services Administration;
2004.
-
Henry J. Kaiser Family Foundation, NASTAD. National
ADAP Monitoring Project. 2006 Annual Report. April 2006. Available
at: www.kff.org/hivaids/hiv033006pkg.cfm.
-
National Association of
State and Territorial AIDS Directors. ADAP Funding Watch; 2006, March.
Available at: www.nastad.org/documents/public/publicpolicy/ADAP-Watch-Apr-06.pdf
-
Backus
LI, Boothroyd D, Deyton LR. HIV, hepatitis C and HIV/hepatitis C
virus co-infection in vulnerable populations. AIDS. 2005;19(suppl
3):S13-9.
-
Goulet JL, Fultz SL, McGinnis KA, Justice AC. Relative
prevalence of comorbidities and treatment contraindications in HIV-mono-infected
and HIV/HCV-co-infected veterans. AIDS. 2005;19(suppl 3):S99-105.
-
Rosenberg
SD, Drake RE, Brunette MF, Wolford GL, Marsh BJ. Hepatitis C virus
and HIV co-infection in people with severe mental illness and substance
use disorders. AIDS. 2005;19(suppl 3):S26-33.
-
Taylor LE, Gholam PM,
Schwartzapfel B, Rich JD. Hepatitis C treatment in an HIV-HCV-coinfected
patient with drug addiction and psychiatric illness: a case report.
AIDS Read. 2005;15(11):629-31, 634-6, 638.